Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration
Biogen will pay $165m up front for ex-North American rights to Stoke’s Phase III-ready Dravet syndrome candidate, an antisense drug offering disease-modifying potential.
Biogen will pay $165m up front for ex-North American rights to Stoke’s Phase III-ready Dravet syndrome candidate, an antisense drug offering disease-modifying potential.